Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
MAHA ELEVATE is structurally a research grant program dressed in value-based care language, not a traditional CMMI payment model. The Section 1115A authority is standard CMMI ground, but the cooperative agreement vehicle — distributing roughly $3.33 million per awardee across 30 slots over three years (assuming equal allocation of the $100M total) — means recipients are grant recipients, not payment model participants. There are no shared savings tracks, no benchmark calculations, no quality withhold reconciliation cycles. This is a deliberate design choice that lowers the operational barrier to entry but fundamentally caps the financial upside.
The structure reveals two distinct CMS strategic objectives running in parallel. First, CMMI under Abe Sutton is generating an evidence base for future Original Medicare coverage determinations — functional and lifestyle medicine interventions that currently have no billing pathway in fee-for-service get three years of federally funded data collection, after which CMS holds the option to create new benefit categories or launch a scaled payment model. Second, the model is the operational arm of the broader MAHA policy agenda under RFK Jr. and HHS, providing tangible programmatic substance to an otherwise rhetorical campaign against chronic disease.
The three reserved dementia slots out of 30 total awards is the single most consequential design detail buried in the program materials. Dementia interventions in Medicare carry enormous downstream cost implications — dementia beneficiaries are among the highest-cost cohort in Original Medicare. Reserving 10% of award capacity for dementia signals that CMS views this condition as the highest-priority validation target, and organizations with documented lifestyle/functional medicine programs for cognitive decline are positioned for near-certain selection if their applications are technically sound.
The requirement that all proposals include nutrition or physical activity as core components is a meaningful constraint that filters out narrower behavioral health or pharmaceutical-adjacent interventions. The "supported by peer-reviewed literature" standard with actual PDF citation requirements and physical text highlighting — not just bibliographic links — reflects awareness of prior grant abuse patterns and a deliberate attempt to hold the evidence bar at genuine pre-existing efficacy, not aspirational claims.
Hidden risk: The cost savings plan requirement does not demand demonstrated savings during the performance period, only a credible financial model projecting when net Medicare FFS savings would materialize if the intervention were covered at scale. This is methodologically permissive. Organizations can model optimistic assumptions with limited accountability during the award period. However, CMS's stated intent to use this data for future coverage determinations means the quality of the financial modeling will directly influence whether any downstream model is designed favorably for the originating intervention type. Weak modeling now creates adverse precedent.
Assuming equal distribution, $3.33M per awardee over 36 months equals approximately $1.11M per year in cooperative agreement funding. This is program delivery capital, not profit — it must cover staffing, patient-facing services, data infrastructure, and CMS reporting requirements.
Break-even estimation: A functional medicine program serving Medicare beneficiaries with group-based interventions (the lowest-cost delivery model) typically requires at minimum one full-time certified practitioner, one care coordinator, and a data/reporting function. Conservative staffing costs in a mid-market geography: $180K–$220K annually for clinical staff plus $60K–$80K for data coordination, totaling $240K–$300K in personnel alone. Add overhead, technology, and compliance: realistic all-in operating cost runs $400K–$600K per year for a minimum viable program. That leaves $510K–$710K annually for actual service delivery and patient-facing costs — viable for a cohort of 150–300 beneficiaries per year depending on intervention intensity.
CMS will set minimum beneficiary enrollment targets based on applicant projections during the award process. Organizations that project aggressively to appear competitive but under-deliver face clawback risk and reputational damage in future CMMI interactions.
Best case: A large academic medical center or integrated health system with existing lifestyle medicine infrastructure absorbs administrative overhead through existing operations, deploys the cooperative agreement funding almost entirely toward patient services, and enrolls 500+ beneficiaries annually. Grant fully covers marginal program costs; institution simultaneously advances research publication pipeline and positions its intervention protocol for future CMS coverage. Net financial benefit including indirect research value: $2M–$4M over the award period beyond direct grant funding.
Worst case: A standalone functional medicine center without prior Medicare data collection infrastructure builds compliance systems from scratch. Technology costs ($150K–$250K for HIPAA-compliant data infrastructure), unexpected IRB requirements, and recruitment shortfalls consume the grant. Program delivers fewer than 100 beneficiaries per year against a CMS minimum target of 200+. Result: CMS non-renewal for Cohort 2, organizational reputational cost, and no sustainable revenue pathway post-award. Net loss: $500K–$1M in staff and infrastructure investment with no scalable output.
Cash flow note: Cooperative agreements typically fund on a reimbursement or draw-down basis, not upfront. Organizations without working capital reserves of $200K–$400K will face operational cash crunches in the first six to twelve months before reimbursement cycles stabilize.
Advantaged: Academic medical centers and integrated health systems with existing lifestyle medicine or integrative medicine departments. They have peer-reviewed publication pipelines satisfying the evidence requirement, existing IRB infrastructure, CEHRT systems for data collection, and the administrative capacity to manage federal cooperative agreements. For these organizations, MAHA ELEVATE is a grant that validates an existing cost center, potentially accelerating internal investment in functional medicine programs ahead of future coverage expansion.
Advantaged: FQHCs and Rural Health Clinics that serve high-burden chronic disease populations and have existing federal grant management infrastructure. Their patient populations directly reflect the Original Medicare FFS demographic that CMS needs for generalizable evidence, and their inclusion aligns with CMS's equity framing.
Disadvantaged: Standalone functional and lifestyle medicine practices. They typically lack Medicare claims data access, IRB relationships, and the administrative bandwidth to meet federal data reporting requirements. The application alone — 15-page project narrative, multiple structured tables, PDF citation management, financial modeling, organizational charts, and partnership documentation — is a substantial burden for small organizations without grants management staff. Many of the organizations most clinically qualified to deliver these interventions will not successfully navigate the application process.
Market consolidation implication: MAHA ELEVATE will accelerate partnership formations between community-based functional medicine providers and larger health systems or ACOs. The eligible applicant list explicitly includes ACOs alongside community organizations and senior living communities. Expect ACOs with MSSP Track participation to recruit lifestyle medicine centers as delivery partners, absorbing the intervention delivery capability while the ACO manages the federal contracting and data obligations. This positions ACOs as the dominant implementation vehicle, extracting value from the grant while smaller functional medicine providers gain patient volume but limited strategic control.
Interaction with MSSP/MA: MAHA ELEVATE explicitly tests interventions "not already covered by Original Medicare," which means there is no direct billing conflict with MSSP shared savings calculations. However, if MAHA ELEVATE interventions reduce hospitalizations and ED utilization among FFS beneficiaries, MSSP ACOs co-enrolled in the model will benefit from improved cost performance — a compounding financial incentive for ACO participation. MA plans have no direct role in this model (Original Medicare only) but should monitor coverage determination outcomes closely: if CMS adds functional medicine benefits to the FFS benefit package post-evaluation, MA plans will face actuarial pressure to match.
Physicians: Independent physicians in functional, integrative, or preventive medicine gain their first realistic pathway to Medicare reimbursement for services they currently bill out-of-pocket or not at all. The cooperative agreement doesn't create a billing code, but it creates organizational revenue that can support their clinical work. The risk is subordination — physicians at partner organizations may find their clinical protocols reviewed and constrained by CMS data collection requirements and IRB oversight structures they've never navigated.
Health systems: For systems with underutilized wellness or integrative medicine departments, MAHA ELEVATE is a margin-improvement vehicle. The grant offsets program costs while generating research outputs. Systems should assess whether their functional medicine footprint is large enough to meet CMS's minimum beneficiary enrollment targets; those with fewer than 500 Medicare FFS patients in targeted chronic condition populations should consider partnership aggregation strategies before applying independently.
Hospitals: Minimal direct operational relevance for acute care hospitals unless they have outpatient wellness infrastructure. The long-term signal — that CMS intends to create coverage pathways for lifestyle interventions — is a strategic prompt for hospitals to evaluate whether investing in ambulatory prevention programs now positions them advantageously for future payment model design.
MA plans: The model is Original Medicare-only and does not directly affect MA. However, the evidence generation mission is explicitly linked to "future Original Medicare coverage determinations." Plans should track evaluation outcomes: new FFS covered benefits create mandatory actuarial adjustments in MA bid development. Plans with commercial lifestyle medicine partnerships should consider whether voluntary participation in a future scaled model — if CMS launches one — could improve Star Ratings performance through improved chronic disease management metrics.
Bottom line: MAHA ELEVATE is a $100M federal investment in building the evidence base CMS needs to justify a future payment model — one that could eventually restructure how preventive and lifestyle medicine services are reimbursed across all of Original Medicare. The 30 awardees are essentially paid to run the pilot studies that would justify that restructuring. Organizations that understand this dynamic and position their applications to generate the most policy-usable evidence — not just the most compelling clinical story — will extract the most long-term strategic value from participation.